VGB-Ex01
/ Shanghai Vitalgen BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 17, 2023
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
(clinicaltrials.gov)
- P=N/A | N=2 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting ➔ Recruiting
Enrollment open • Beta-Thalassemia • Genetic Disorders
1 to 1
Of
1
Go to page
1